Report Overview

The global drug delivery systems market was pegged at US$ 213.52 billion in 2021 and is expected to register a revenue CAGR of 6.10% during the forecast period. 

Market Fundamentals 

A drug delivery system is a formulation or medical device that helps active pharmaceutical ingredients reach the active site and achieve the required therapeutic effect safely and effectively. Drugs are administrated by various routes such as oral, parenteral, nasal, transdermal, etc., to achieve a maximum therapeutic effect with minimal time. 

Drug delivery systems are classified into advanced drug delivery systems, conventional drug delivery systems, targeted drug delivery systems, etc. Advanced drug delivery systems are focused on delivering the drug to the active site by bypassing the first-pass effect, which increases the potential therapeutic effect and efficacy. 

[23423434]

Market Dynamics

The global drug delivery systems market revenue growth is mainly driven by the growing prevalence of infectious and chronic diseases and increasing demand for novel drug delivery systems. Additionally, the growing demand for precision medicine, innovative medicine, vaccines, and biologics is contributing to the revenue growth of the global drug delivery systems market. Moreover, increasing demand for home healthcare and the growing availability of innovative medical devices are fueling the revenue growth of this market. However, the imposition of strict regulations by regulatory bodies, challenges associated with drug delivery systems, and routes of administration are supporting the revenue growth of the global drug delivery systems market. 

Market Ecosystem

The global drug delivery systems market is analyzed from three perspectives: type, application, and region.

Drug Delivery Systems Market by Type

Based on type, the global drug delivery systems market is segmented into inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery systems, carrier-based drug delivery systems, oral drug delivery systems, injection-based drug delivery systems, and others. 

The Oral drug delivery system segment is leading the global drug delivery systems market owing to highly safe and convenient methods of administration for a wide range of treatments with lesser adverse effects. Additionally, non-invasiveness, the convenience of self-administration, cost-effectiveness, and better patient compliance are contributing to the revenue growth of this segment. 

The Injection-based drug delivery system segment is expected to register the highest revenue CAGR during the forecast period owing to the increasing rates of infectious and chronic diseases, growing vaccination drive for COVID-19, tuberculosis, hepatitis, etc., and faster therapeutic effects. 

Drug Delivery Systems Market by Application

[8434534]

Based on application, the global drug delivery systems market is segmented into the central nervous system, ophthalmology, infections, cardiovascular diseases, oncology, urology, diabetes, and others. 

The Oncology segment is leading the global drug delivery systems market in terms of revenue share. The large revenue share of this segment can be attributed to the increasing prevalence of cancer and the growing demand for innovative drugs and precision medicine. Additionally, increasing demand for novel drug delivery systems, and growing government initiatives are contributing to revenue growth of the global drug delivery systems market in the oncology segment.

Drug Delivery Systems Market by Region

Based on region, the global drug delivery systems market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global drug delivery systems market in terms of revenue share. The large revenue share of North America can be attributed to the high prevalence of chronic and infectious diseases in the region, the increasing adoption of novel drug delivery systems, and the strong presence of key market players. Additionally, the early uptake of advanced technologies, the existence of developed infrastructure, and favorable reimbursement policies are contributing to the revenue growth of the North American drug delivery systems market. 

Asia Pacific is also expected to register exponential revenue growth owing rapid evolution of healthcare infrastructure and improving uptake of novel drug delivery systems.

Competitive Landscape

The prominent players operating in the global drug delivery systems market are: 

• Baxter International Inc.
• Becton, Dickinson, and Company
• Bayer AG
• F. Hoffmann-La Roche, Ltd.
• Gerresheimer AG
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer, Inc.
• Sibiono GeneTech Co. Ltd.
• uniQure N.V.
• West Pharmaceutical Services Inc. 

Strategic Developments

• In June 2022, Gufic Biosciences launched new drug delivery system dual chamber bags in India at an affordable price by collaborating with a French counterpart. Dual chamber IV bags are made up of polypropylene (DEHP free) with a peelable aluminum foil which allows for keeping unstable drugs. 
• In May 2022, Medtronic received the United States Food and Drug Administration approval for the next-generation drug-eluting coronary stent the Onyx Frontier Drug Eluting Stent (DES). Onyx Frontier DES is a zotarolimus-eluting coronary stent system that is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus or high bleeding risk, with ischemic heart disease. It is also indicated for treating de novo chronic total occlusions and non-left main bifurcation lesions. 
• In September 2022, Insulet received CE mark approval under the European Medical Devices Regulation for Omnipod 5 automated insulin delivery system for type 1 diabetes. Ominipod 5 is an automated insulin delivery system integrated with the Dexcom G6 continuous glucose monitoring (CGM) to auto-adjust body insulin levels with SmartAdjust technology

Frequently Asked Questions About This Report